Compare AFLAC Incorporated (AFL) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs Neurocrine Biosciences Inc — how do they compare? AFLAC Incorporated trades at $121.06 (market cap $60.70B), while Neurocrine Biosciences Inc trades at $151.75 (market cap $16.46B). The key difference: AFLAC Incorporated is far larger — about 3.7× Neurocrine Biosciences Inc's market cap, and AFLAC Incorporated pays a 2.02% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| AFL | NBIX | |
|---|---|---|
Market Cap | $60.70B | $16.46B |
Sector | Financials | Health |
52-Week High | $129.55 | $185.50 |
52-Week Low | $103.55 | $123.10 |
Enterprise Value | $70.65B | $16.48B |
Dividend Yield | 2.02% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
